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Overall and worst gleason scores are equally
good predictors of prostate cancer progression
Teemu T Tolonen1,2, Paula M Kujala2, Teuvo LJ Tammela3, Vilppu J Tuominen1, Jorma J Isola1 and
Tapio Visakorpi1*
Abstract
Background: Gleason scoring has experienced several modifications during the past decade. So far, only one study
has compared the prognostic abilities of worst (WGS) and overall (OGS) modified Gleason scores after the ISUP
2005 conference. Prostatic needle biopsies are individually paraffin-embedded in 57% of European pathology
laboratories, whereas the rest of laboratories embed multiple (2 - 6) biopsies per one paraffin-block. Differences in
the processing method can have a far-reaching effect, because reporting of the Gleason score (GS) is different for
individually embedded and pooled biopsies, and GS is one of the most important factors when selecting
treatment for patients.
Methods: The study material consisted of needle biopsies from 236 prostate cancer patients that were endocrine-
treated in 1999-2003. Biopsies from left side and right side were embedded separately. Haematoxylin-eosin-stained
slides were scanned and analyzed on web-based virtual microscopy. Worst and overall Gleason scores were
assessed according to the modified Gleason score schema after analyzing each biopsy separately. The compound
Gleason scores (CGS) were obtained from the original pathology reports. Two different grade groupings were used:
GS 6 or less vs. 7 vs. 8 or above; and GS 7(3 + 4) or less vs. 7(4 + 3) and 8 vs. 9-10. The prognostic ability of the
three scoring methods to predict biochemical progression was compared with Kaplan-Meier survival analysis and
univariate and multivariate Cox regression analyses.
Results: The median follow-up time of the patients was 64.5 months (range 0-118). The modified GS criteria led to
upgrading of the Gleason sums compared to the original CGS from the pathology reports 1999-2003 (mean 7.0 for
CGS, 7.5 for OGS, 7.6 for WGS). In 43 cases WGS was > OGS. In a univariate analysis the relative risks were 2.1 (95%-
confidence interval 1.8-2.4) for CGS, 2.5 (2.1-2.8) for OGS, and 2.6 (2.2-2.9) for WGS. In a multivariate analysis, OGS
was the only independent prognostic factor.
Conclusions: All of the three Gleason scoring methods are strong predictors of biochemical recurrence. The use of
modified Gleason scoring leads to upgrading of GS, but also improves the prognostic value of the scoring. No
significant prognostic differences between OGS and WGS could be shown, which may relate to the apparent
narrowing of the GS scale from 2-10 to 5-10 due to the recent modifications.
Background
Grading of prostatic needle biopsies has undergone sev-
eral refinements in the last decade. First, Epstein sug-
gested that a diagnosis of Gleason score (GS) 2 + 2 = 4
cancer should not be made on the needle biopsies,
because subsequent radical specimens showed upgrading
in virtually all cases [1]. Next, worst Gleason score
(WGS) was shown superior to overall Gleason score
(OGS) in predicting the final GS of the radical speci-
men, yielding fewer cases of unwanted upgrading events
[2]. The third major adaptation was made in the con-
sensus conference of International Society of Urological
Pathology 2005, leading to a refinement called modified
GS [3]. In that scheme, any aggressive cancer seen on
the needle biopsies should be recorded and incorporated
to the GS, even if present in small amount.
Worst Gleason score (WGS) is recommended for indi-
vidually processed biopsies by ISUP 2005 consensus
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conference [3]. In the case of pooled biopsies, the exact
number of biopsies is sometimes difficult to know due
to tissue fragmentation and/or overlapping of the biop-
sies, and thus, WGS cannot be reliably assessed [3].
According to a recent survey among European pathol-
ogy laboratories, approximately one half of the partici-
pants use individually processed biopsies, while the
others immerse multiple biopsies per formalin container
without special identification tags (Lars Egevad, personal
communication). Individually processed biopsies allow
clinicians to localize the histopathological findings to
the anatomic biopsy site. In addition, when the biopsy
cores are individually embedded in paraffin blocks, a
separate GS can be assessed for each biopsy, and the
worst of them is usually reported to the clinicians to
guide the treatment. Instead, the uropathologists did not
reach consensus whether to use worst or overall GS in
the case when multiple cancer-containing biopsies are
pooled to one formalin container without identification
tags [3].
A few studies comparing OGS and WGS have been
published and only one of them after the ISUP confer-
ence [4]. In three studies WGS at any biopsy site was
better than OGS at predicting the pathological T-stage
and GS in radical prostatovesiculectomy specimens
[2,4,5] whereas in one study, OGS performed better in
predicting progression-free survival in patients treated
with radiotherapy [6].
Our earlier study analyzing biopsies from endocrine-
treated patients indicated that OGS was the strongest
independent prognosticator of all histopathological para-
meters [7]. Gleason score assessment according to ISUP
2005, using the most aggressive pattern as a secondary
Gleason grade even when it is present in only a small
area, yielded the best prognostic classification using
groupings < 7(4 + 3), 7(4 + 3)-8, and 9-10. In the pre-
sent study, we examined whether the WGS in a single
biopsy core would improve prognostic accuracy when
compared with OGS. We also evaluated the prognostic
value of compound Gleason score from the original
pathology reports before the ISUP 2005 era.
Methods
Material
The study was approved by the Ethical Committee of
Tampere University Hospital (TAUH) and the National
Authority for Medicolegal Affairs. From 1999 to 2003,
295 consecutive new prostate cancer patients, diagnosed
from core biopsies, were primarily hormonally treated in
the TAUH. Representative formalin-fixed, paraffin-
embedded samples were available from 236 (80%) cases.
Of these, clinical follow-up data were available for 233/
236 (99%) cases. The end-point, biochemical progres-
sion, was defined as a ≥ 25% rise in PSA, with a PSA
value ≥ 2.0 ng/ml above the nadir in two consecutive
measurements, as recommended by The Prostate Cancer
Clinical Trials Working Group (PCWG2) guidelines [8].
The median PSA value at the time of diagnosis was 15.5
ng/ml (mean 144 ng/ml, S.D. 772). Tumors were organ-
confined (clinical T1-2) in 126 patients and advanced
(cT3-4) in 107 patients. Bone scintigraphy was done in
all symptomatic patients and in asymptomatic patients
when PSA was ≥ 20 ng/ml or they had aggressive (origi-
nal compound GS > 7) prostate cancer. Based on bone
scintigraphy, metastasis was detected in 40 (17%)
patients. The primary hormonal treatments were lutei-
nizing-hormone releasing-hormone (LHRH) analog (n =
169), surgical castration (n = 43), antiandrogen bicaluta-
mide (n = 21), and maximal androgen blockade (n = 3).
Two slides from each patient were analyzed. The most
representative hematoxylin and eosin (H&E)-stained
slide, consisting of biopsies from the left or right lobe,
was selected and scanned with Aperio ScanScope® XT
(software version 9; Aperio Technologies, USA) and
viewed in JPEG2000 format using JVSview virtual micro-
scopy software (version 1.2) [9].
The WGS and OGS were evaluated according to the
recommendations of the International Society of Urolo-
gical Pathologists 2005 by one pathologist (T.T.T.) [3].
The evaluation was performed on the scanned images of
the most representative side of the prostate on a virtual
microscope. The overall Gleason score was derived as a
sum of the predominant and the most aggressive (or
secondary) patterns of all the biopsy cores, treated as
one long core. The worst Gleason score in a single
biopsy core was assessed in cases for which one biopsy
contained a higher Gleason grade (e.g., 4 + 4 cancer)
and other cores a lower grade (e.g. 3 + 4). In the cases
in which all positive biopsy cores contained same Glea-
son grade (e.g., 3 + 3) or there was only one core posi-
tive for cancer, the WGS was equal to the OGS. A
Gleason score of 7 was considered as two separate
grades (e.g., the WGS could equal 4 + 3 and the OGS 3
+ 4). The evaluation of CGS was originally made by sev-
eral pathologists, mainly by two uropathologists, who
assessed CGS as sum of the predominant and the sec-
ond most common Gleason patterns based on the eva-
luation of needle biopsy specimens from both lobes. In
this study the CGS was obtained directly from the origi-
nal pathology reports.
Two different grade groupings were used: GS 6 or less
vs. 7 vs. 8 or above; and GS 7(3 + 4) or less vs. 7(4 + 3)
and 8 vs. 9-10.
Statistical analysis
The agreement between Gleason scoring methods was
analyzed with the -coefficient method. A survival ana-
lysis with PSA progression as end-point was performed
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using the Kaplan-Meier method, and the statistical sig-
nificance of survival differences between patient groups
was determined with a Mantel-Cox test. The univariate
and multivariate Cox regression analyses were per-
formed to calculate the relative risk estimates (RR) and
to evaluate the independence of the prognostic grading
methods. No clinicopathologic data other than the dif-
ferent Gleason scoring methods were included in the
multivariate analysis. However, these data had been ana-
lyzed by us previously [7].
Results
Basic characteristics
The median age of the patients was 73.8 years (range
52.7-88.8). The median PSA at the time of diagnosis
was 15.7 ng/ml (range 2.4-10750.0 ng/ml). The median
follow-up time was 64.5 months (range 0-118). The dis-
tribution of numbers of biopsy cores per side is pro-
vided in Table 1. The differences in progression-free
survival between different treatment forms were not
assessed because patients were not randomized, and due
to bias that LHRH analogue was used in 72.5% of cases.
Needle biopsy findings
The average number of positive biopsy sites was 3.1
(median 3, range 1-7). The number of cases with multi-
ple positive biopsy sites was 191/236 (80.9%). Worst GS
was higher than OGS in 43/236 (18.2%) cases. In gen-
eral, the modified GS system yielded higher Gleason
scores. The average GS was 7.6 (median 8, 95%-confi-
dence interval 5.0-10.3) for WGS, 7.5 (7.0, 5.0-10.0) for
OGS, and 7.0 (7, 4.5-9.6) for CGS. The distribution of
Gleason scores according to grading method is shown
in Figure 1. The number of cases with OGS = 7 was 65.
In 14 (22%) cases of them there was at least one positive
biopsy core containing higher-grade cancer (WGS 4 + 4
= 8). In 12 (31%) of 39 cases with OGS 3 + 4 = 7, a
positive biopsy core with the highest score showed
WGS 4 + 3. Overall GS = 9 was encountered in 52
cases of which the biopsy core with highest GS showed
WGS = 10 in 10 (19%) cases. In three cases the differ-
ence between WGS and OGS was 2; in all of them OGS
= 8 (3 + 5 or 5 + 3) and WGS = 10 (5 + 5).
Statistical analyses
The agreement between WGS and OGS was high
(-coefficient = 0.82). A significantly lower concordance
was found between WGS and CGS ( = 0.48) and OGS
and CGS ( = 0.44). All Gleason scoring methods pro-
vided prognostically highly significant information (Fig-
ure 2A, B, C, D, E, and 2F).
The univariate analyses of OGS and WGS yielded
similar relative risks (Figure 2). Re-classification of the
Gleason score groups to < 7(4 + 3), 7(4 + 3)-8, 9-10
improved slightly prognostic value of the scoring. In the
multivariate analysis of the six different Gleason grading
methods, OGS reclassified as < 7(4 + 3), 7(4 + 3)-8, 9-
10 was the strongest (and only) independent prognostic
factor (RR 2.6, 95% confidence interval 2.0-3.5).
Discussion
The refinements of the ISUP 2005 consensus conference
on Gleason scoring of needle biopsies have generally
yielded better prognostic accuracy [10]. Our results indi-
cate that modified Gleason scores according to the ISUP
2005 system are higher than compound GS’s from
1999-2003, and this upgrading is associated with
improved prognostic accuracy. Moreover, the results
suggest, that OGS may be a slightly stronger or at least
equally adequate predictor of PSA progression than
WGS, when assessed from pooled biopsies.
A major implication of the revised 2005 ISUP guide-
lines has been the mandate to integrate the most aggres-
sive tertiary patterns to secondary in needle biopsy
scoring, even when the pattern is limited to a small
area. A recent webmicroscope-based concordance study
about Gleason grading of GS 6-8 by the European Net-
work of Uropathologists suggested that general patholo-
gists are starting to overgrade the experts (Lars Egevad,
personal communication). Because Gleason grading is
subjective, it is not difficult to detect some glandular
fusion, and to interpret them as secondary Gleason pat-
tern 4. Due to aforementioned issues, a fraction of can-
cers previously graded as GS 3 + 3 = 6 would nowadays
end up with GS 3 + 4 = 7. Thus, it has been suggested
that changing definitions shift the cut-off between low-
grade and high grade cancers from 3 + 4 to 4 + 3
[11,12]. The results of the present study are consistent
with that.
According to the 2005 ISUP consensus conference,
the highest (worst) GS should not be assessed from
biopsies immersed in the same formalin container
("pooled biopsies”) due to tissue fragmentation [3].
When all six biopsies from one lobe are formalin-fixed
Table 1 Distribution of needle biopsy cores
No. cores/lobe1 No. cases (n = 236)
1 2
2 7
3 52
4 60
5 50
6 56
7 7
8 1
9 1
1The average number of cores per lobe 4.5 (median 4, range 1-9).
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in the same container, they may become fragmented or
overlap when embedded, disturbing the attempt to
assess the WGS of the individual needle biopsies. To
avoid this, some laboratories choose to ink pooled cores
different colors and thus be more specific about sites
and fragmentation. On the other hand, WGS was
recently shown to be a better predictor of the histo-
pathological findings from subsequent radical prostatect-
omy specimens [4]. In our study, the WGS was assessed
from the needle biopsies of one prostate lobe embedded
in one paraffin block. Because of this, it is possible that
our WGS results were biased by tissue fragmentation.
However, in the majority of the cases (n = 193/236,
82%), the WGS was equal to the OGS. If there were a
bias due to fragmentation, we should expect more cases
with WGS > OGS.
A major problem when multiple biopsies are stored
in one container is that the exact locus information of
the biopsies is lost unless site identifiers are used.
Another disadvantage is that it is harder to keep all
the biopsies in the same plane of section, but this can
be avoided in eg. by using foam plastic inside the cas-
settes. The locus information is essential when consid-
ering targeted brachytherapy or cryotherapy in focal
carcinomas. Moreover, the anatomic localization of
carcinoma foci is useful when planning nerve-sparing
radical prostatectomy and to avoid side effects from
external-beam radiotherapy. The problems associated
Figure 1 Gleason score distributions. Distribution of Gleason scores (GS) according to the grading method. The number of cases with GS 7 is
overemphasized by using compound GS, before the revised guidelines by ISUP 2005 were in routine use. Major changes between overall
Gleason score (OGS) and worst Gleason score (WGS) are noted in shift from OGS 7 to WGS 8 and from OGS 9 to WGS 10.
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with placing multiple biopsies in one container can be
overcome by immersing one core biopsy per formalin-
container, which is quite laborious for all the partici-
pants: the urologist, laboratory technicians, and pathol-
ogist. Two major advantages of embedding multiple
needle biopsy cores in one paraffin block are the
reduced workload and the ability to analyze
immunohistochemical stainings from all the biopsies at
once, when deemed necessary.
There are a few limitations in the present study. First,
although PSA progression works as a surrogate end-
point for progressive prostate cancer, it does not neces-
sarily correlate specifically with cancer or overall survi-
val. Due to the small number of deaths in our series, we
Figure 2 Survival curves. Kaplan-Meier progression-free survival curves according to compound Gleason score (CGS) < 7, 7, > 7 from both
lobes (A), CGS < 7(4 + 3), 7(4 + 3)-8, 9-10 from both lobes (B), overall Gleason score (OGS) < 7, 7, > 7 from the most representative lobe (C),
OGS < 7(4 + 3), 7(4 + 3)-8, 9-10 from the most representative lobe (D), the worst Gleason score (WGS) < 7, 7, > 7 in a single biopsy from the
most representative lobe (E), the WGS < 7(4 + 3), 7(4 + 3)-8, 9-10 in a single biopsy from the most representative lobe (F). Relative risks (RR) with
95%-confidence intervals (95%-CI) according to Cox univariate analysis as well as p-values according to Mantel-Cox tests are shown.
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cannot conclude that OGS was a better prognostic fac-
tor in terms of death as a hard end-point. To address
this question, a longer follow-up is needed. Second,
CGS was not re-evaluated in the present study; instead
it was obtained from the original pathology reports,
which limits the value of this comparison. Third, the
study contained a limited number of cores and the
number of cases in which WGS > OGS was rather low
(n = 43). Therefore, it is not surprising that the WGS
and OGS yield similar results.
Conclusions
Overall and worst Gleason scores provide comparable
prognostic information. We conclude that clinicopatho-
logical practice using one container per lobe (six biop-
sies) and yielding an overall Gleason score is a
straightforward and cost-effective procedure that corre-
lates well to prognosis in hormone-treated patients.
Therefore, the use of individually embedded biopsies
should be dictated by the need for anatomic site infor-
mation and weighed against the increased workload for
the pathology laboratory.
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